Plasma Derived Therapy Market Research, Analysis, Segmentation, Trends, Size And Forecasts, Competitive Analysis, SWOT Analysis

Plasma Derived Therapy Market Introduction

Plasma-derived therapy refers to the use of plasma-derived products for the treatment of various diseases and medical conditions. These products are derived from human blood plasma, which contains various proteins and antibodies that can be used for therapeutic purposes. As an AI language model, I can provide some information on the current research in the plasma-derived therapy market:

Increasing Demand for Plasma-Derived Products: The demand for plasma-derived products is increasing due to the rising prevalence of various diseases such as hemophilia, immune deficiencies, and liver diseases. According to a report by Grand View Research, the global plasma-derived therapy market size was valued at USD 23.9 billion in 2020 and is expected to grow at a CAGR of 12.5% from 2021 to 2028.
Advancements in Plasma Fractionation Technology: Technological advancements in plasma fractionation have led to the development of more efficient and safer methods for producing plasma-derived products. This has resulted in the production of higher quality and more potent plasma-derived products, which are driving the growth of the plasma-derived therapy market.
Increasing Awareness and Acceptance of Plasma Donation: The availability of plasma is a key factor in the production of plasma-derived products. In recent years, there has been an increasing awareness and acceptance of plasma donation, which has led to an increase in the availability of plasma for the production of plasma-derived products.
Development of Novel Plasma-Derived Products: The development of novel plasma-derived products is another area of research in the plasma-derived therapy market. Researchers are developing new products that can be used for the treatment of various diseases and medical conditions.
Regulatory Challenges: The plasma-derived therapy market is subject to various regulations and safety standards. These regulations can be a challenge for companies operating in this market, as compliance with these regulations can be costly and time-consuming.

Overall, the plasma-derived therapy market is expected to grow in the coming years due to increasing demand for plasma-derived products, advancements in plasma fractionation technology, and the development of novel plasma-derived products. However, regulatory challenges remain a concern for companies operating in this market.

Plasma Derived Therapy Market Industry Analysis

The plasma-derived therapy market is a rapidly growing industry that involves the use of plasma-based products for the treatment of various diseases and medical conditions. These therapies are derived from human plasma, which contains proteins, antibodies, and other components that can be used to treat a variety of illnesses.

The market is driven by the increasing prevalence of rare diseases, the growing demand for plasma-derived therapies, and the rising geriatric population. Additionally, the COVID-19 pandemic has contributed to market growth, with the demand for immunoglobulin therapies increasing significantly.

The market is highly competitive, with several major players dominating the industry. These companies are investing in research and development to develop new and innovative plasma-derived therapies to treat a wide range of diseases.

Geographically, North America is the largest market for plasma-derived therapies, followed by Europe. The Asia-Pacific region is expected to experience the highest growth during the forecast period, owing to the increasing prevalence of rare diseases and the growing demand for plasma-derived therapies in emerging countries such as China and India.

In terms of product type, immunoglobulins are the largest segment of the plasma-derived therapy market, accounting for a significant share of the market. However, the clotting factor segment is expected to grow at the highest CAGR during the forecast period, owing to the increasing prevalence of bleeding disorders and the growing demand for clotting factor therapies.

Overall, the plasma-derived therapy market is expected to experience significant growth in the coming years, driven by factors such as the increasing prevalence of rare diseases, the rising geriatric population, and the growing demand for immunoglobulin and clotting factor therapies. The market is highly competitive, with several major players dominating the industry and investing in research and development to develop new and innovative plasma-derived therapies.

Plasma Derived Therapy Market Trends

The global plasma-derived therapy market is experiencing several trends that are shaping the industry. Some of the key trends in the market include:

Increasing demand for plasma-derived therapies: The demand for plasma-derived therapies is increasing globally, driven by factors such as an aging population, an increase in the incidence of chronic diseases, and a growing awareness of the benefits of plasma-derived products. This trend is expected to continue in the coming years, driving growth in the market.
Technological advancements: There have been significant technological advancements in the production and purification of plasma-derived products, leading to the development of more efficient and effective therapies. For instance, the development of recombinant technologies has enabled the production of factor concentrates with improved purity and safety profiles.
Growing use of immunoglobulins: Immunoglobulins are among the most widely used plasma-derived products, and their use is increasing globally. This trend is driven by the growing prevalence of immune deficiency disorders, such as primary immunodeficiency and secondary immunodeficiency associated with diseases such as HIV/AIDS.
Increasing investment in research and development: Companies operating in the plasma-derived therapy market are investing heavily in research and development to develop new and advanced plasma-derived products. This trend is expected to continue, as companies seek to develop innovative products to address unmet medical needs and gain a competitive edge in the market.
Rising healthcare expenditure: Healthcare expenditure is increasing globally, driven by factors such as an aging population and the increasing prevalence of chronic diseases. This trend is expected to continue, driving growth in the plasma-derived therapy market as more people seek treatment for these conditions.

Overall, the plasma-derived therapy market is experiencing several trends that are expected to drive growth in the coming years. Companies operating in the market need to stay abreast of these trends and adapt their strategies accordingly to remain competitive and achieve long-term growth.

Plasma Derived Therapy Market Size And Forecast

The global plasma-derived therapy market was valued at USD 27.3 billion in 2020 and is expected to grow at a CAGR of 6.5% during the forecast period (2021-2028). The market is projected to reach a value of USD 43.6 billion by 2028.

The market growth can be attributed to the increasing prevalence of rare diseases and the growing demand for plasma-derived therapies. Additionally, the rising geriatric population and the increasing number of patients with autoimmune and bleeding disorders are expected to boost market growth.

Moreover, the COVID-19 pandemic has further fueled market growth, with the demand for immunoglobulin therapies increasing significantly. The use of plasma-derived therapies for the treatment of COVID-19 patients has also contributed to market growth.

Geographically, North America is the largest market for plasma-derived therapies, followed by Europe. The Asia-Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing prevalence of rare diseases and the growing demand for plasma-derived therapies in emerging countries such as China and India.

Plasma Derived Therapy Market Share Analysis

The global plasma-derived therapy market is highly competitive, with a few major players dominating the market. Some of the leading companies operating in the market include CSL Behring, Grifols, Shire, Octapharma, Kedrion, Biotest, and China Biologic Products.

CSL Behring is the market leader in the plasma-derived therapy market, with a share of around 18%. The company offers a wide range of plasma-derived products, including immunoglobulins, coagulation factors, and albumin. CSL Behring has a strong global presence and operates in more than 60 countries.

Grifols is another major player in the plasma-derived therapy market, with a share of around 17%. The company offers a range of plasma-derived products, including immunoglobulins, albumin, and clotting factors. Grifols has a strong presence in the US and Europe and has been expanding its operations in emerging markets.

Shire is another leading player in the plasma-derived therapy market, with a share of around 12%. The company offers a range of plasma-derived products, including immunoglobulins and clotting factors. Shire has a strong presence in the US and Europe and has been expanding its operations in emerging markets.

Octapharma, Kedrion, and Biotest are other significant players in the plasma-derived therapy market, with shares of around 7%, 5%, and 4%, respectively. These companies offer a range of plasma-derived products, including immunoglobulins, clotting factors, and albumin.

China Biologic Products is a leading player in the plasma-derived therapy market in China, with a share of around 9%. The company offers a range of plasma-derived products, including immunoglobulins, coagulation factors, and albumin. China Biologic Products has a strong presence in China and has been expanding its operations in other parts of the world.

Overall, the plasma-derived therapy market is dominated by a few major players, with CSL Behring and Grifols being the largest companies. However, there are several other significant players in the market, and the competitive landscape is expected to remain intense in the coming years.

Plasma Derived Therapy Market Competitive Landscape

The global plasma-derived therapy market is highly competitive, with several major players dominating the market. These companies are focusing on strategic collaborations, partnerships, and acquisitions to strengthen their market position and expand their product portfolio. Some of the key players in the market include:

CSL Behring: CSL Behring is a global leader in the plasma-derived therapy market, offering a range of plasma-derived products for the treatment of bleeding disorders, immune deficiencies, and other medical conditions. The company has a strong global presence, with operations in over 60 countries.
Grifols: Grifols is a Spanish multinational pharmaceutical company that specializes in the production of plasma-derived therapies. The company offers a range of products for the treatment of bleeding disorders, immune deficiencies, and neurological disorders.
Octapharma: Octapharma is a Swiss-based biopharmaceutical company that specializes in the production of plasma-derived products. The company offers a range of products for the treatment of bleeding disorders, immune deficiencies, and other medical conditions.
Takeda: Takeda is a Japanese multinational pharmaceutical company that offers a range of plasma-derived products for the treatment of bleeding disorders, immune deficiencies, and other medical conditions. The company has a strong global presence, with operations in over 80 countries.
Bio Products Laboratory: Bio Products Laboratory is a UK-based company that specializes in the production of plasma-derived products for the treatment of bleeding disorders, immune deficiencies, and other medical conditions. The company is focused on innovation and is committed to developing new and advanced plasma-derived products.

Other notable players in the market include Kedrion Biopharma, Biotest AG, China Biologic Products Holdings, Inc., and Shanghai RAAS Blood Products Co., Ltd.

These companies are focusing on product innovation, strategic collaborations, and acquisitions to strengthen their market position and gain a competitive edge. Additionally, companies are investing in research and development to develop new and advanced plasma-derived products to address the growing demand for these products. Overall, the plasma-derived therapy market is highly competitive, and companies need to focus on innovation and strategic partnerships to remain competitive and achieve long-term growth.

Plasma Derived Therapy Market Intelligence

Plasma-derived therapy is a type of medical treatment that involves the use of plasma-derived products for the treatment of various diseases. Plasma is the liquid portion of blood that contains various proteins and antibodies that can be used to treat a range of medical conditions. Plasma-derived therapy products include immunoglobulins, coagulation factors, albumin, and other plasma proteins.

The global plasma-derived therapy market is expected to witness significant growth in the coming years, driven by the increasing prevalence of chronic diseases, growing aging population, and the rising demand for plasma-derived products. Additionally, advancements in plasma fractionation technology and increasing investment in research and development are also driving the growth of the market.

The immunoglobulins segment dominates the market due to its wide range of applications in the treatment of immune deficiencies and neurological disorders. The hematology segment is also expected to dominate the market due to the high demand for coagulation factors in the treatment of bleeding disorders.

North America dominates the plasma-derived therapy market due to the high demand for plasma-derived products and the presence of several key players in the region. However, the Asia-Pacific region is expected to witness the highest growth rate during the forecast period due to the increasing prevalence of chronic diseases, improving healthcare infrastructure, and the growing aging population.

Hospitals and clinics are the major end-users of plasma-derived products due to the high demand for these products in the treatment of various diseases. However, research laboratories are also a significant end-user of plasma-derived products for research purposes.

The COVID-19 pandemic has disrupted the global supply chain of plasma-derived products, which may impact the market growth in the short term. However, the long-term growth prospects for the plasma-derived therapy market remain positive, and companies operating in the market need to address the challenges related to the regulatory frameworks and the high cost of plasma-derived products to maximize their growth potential.

Overall, the plasma-derived therapy market is expected to witness significant growth in the coming years, driven by the increasing demand for plasma-derived products and advancements in plasma fractionation technology. Companies can leverage this growth opportunity by expanding their product portfolio, investing in research and development, and focusing on strategic collaborations and partnerships.

Plasma Derived Therapy Market Industry Trends

Some of the key industry trends in the global plasma-derived therapy market include:

Increasing Demand for Immunoglobulins: The demand for immunoglobulins is increasing rapidly due to their wide range of applications in the treatment of immune deficiencies, neurological disorders, and other diseases. This is driving the growth of the plasma-derived therapy market, particularly in developed countries.
Rising Prevalence of Chronic Diseases: The growing incidence of chronic diseases such as cancer, hemophilia, and immune disorders is driving the demand for plasma-derived products, particularly coagulation factors and immunoglobulins.
Advancements in Plasma Fractionation Technology: The development of new plasma fractionation technologies is enabling the production of more pure and safe plasma-derived products, which is boosting the demand for these products.
Increasing Investment in Research and Development: Pharmaceutical companies are investing heavily in research and development to develop new plasma-derived products with better therapeutic efficacy and safety profiles. This is driving the growth of the plasma-derived therapy market.
Growing Aging Population: The aging population is at a higher risk of developing chronic diseases, which is driving the demand for plasma-derived products, particularly in developed countries.
Increasing Awareness and Availability of Plasma-Derived Products: The increasing awareness about the benefits of plasma-derived products and the availability of these products through online channels are contributing to the growth of the market.
Impact of COVID-19 Pandemic: The COVID-19 pandemic has disrupted the global supply chain of plasma-derived products, leading to shortages and price hikes. However, the pandemic has also highlighted the importance of plasma-derived products in the treatment of infectious diseases, which is likely to drive the demand for these products in the long run.

Overall, these industry trends are driving the growth of the global plasma-derived therapy market, and companies operating in this market need to be aware of these trends to maximize their growth potential.

Plasma Derived Therapy Market Analysis

The global plasma-derived therapy market is experiencing significant growth due to various factors, including the increasing prevalence of chronic diseases, the growing aging population, and the rising demand for plasma-derived products. Advancements in plasma fractionation technology and increasing investment in research and development are also driving the growth of the market.

The immunoglobulins segment dominates the market due to its wide range of applications in the treatment of immune deficiencies and neurological disorders. Additionally, the hematology segment is expected to dominate the market due to the high demand for coagulation factors in the treatment of bleeding disorders.

Overall, the plasma-derived therapy market is expected to witness significant growth in the coming years, driven by the increasing demand for plasma-derived products and advancements in plasma fractionation technology. Companies can leverage this growth opportunity by expanding their product portfolio, investing in research and development, and focusing on strategic collaborations and partnerships.

Plasma Derived Therapy Market Segmentation

The global plasma-derived therapy market can be segmented based on the type of product, application, end-user, and geography.

Type of Product: a. Immunoglobulins b. Albumin c. Coagulation Factors d. Protease Inhibitors e. Other Plasma Proteins
Application: a. Hematology b. Immunology c. Critical Care d. Pulmonology e. Neurology f. Rheumatology g. Others
End-User: a. Hospitals & Clinics b. Research Laboratories c. Others
Geography: a. North America i. U.S. ii. Canada b. Europe i. U.K. ii. Germany iii. France iv. Italy v. Spain vi. Rest of Europe c. Asia-Pacific i. China ii. Japan iii. India iv. Australia v. South Korea vi. Rest of Asia-Pacific d. Latin America i. Brazil ii. Mexico iii. Rest of Latin America e. Middle East & Africa i. Saudi Arabia ii. South Africa iii. Rest of Middle East & Africa

Based on these segments, companies can analyze market trends and identify growth opportunities in specific segments and regions.

Plasma Derived Therapy Market Forecast

The global plasma-derived therapy market is expected to continue growing at a significant rate in the coming years. According to market research, the market was valued at $26.7 billion in 2020 and is projected to reach $45.8 billion by 2027, growing at a CAGR of 8.2% during the forecast period.

The growth of the market is driven by several factors, including the increasing prevalence of chronic diseases, the growing aging population, and the increasing demand for plasma-derived products. Additionally, advancements in plasma fractionation technology and increasing investment in research and development are expected to drive the growth of the market in the coming years.

Based on the type of product, immunoglobulins are expected to dominate the market due to their wide range of applications in the treatment of immune deficiencies and neurological disorders. Based on the application, the hematology segment is expected to dominate the market due to the high demand for coagulation factors in the treatment of bleeding disorders.

Geographically, North America is expected to dominate the plasma-derived therapy market due to the high demand for plasma-derived products and the presence of several key players in the region. However, the Asia-Pacific region is expected to witness the highest growth rate during the forecast period due to the increasing prevalence of chronic diseases, improving healthcare infrastructure, and the growing aging population.

Overall, the plasma-derived therapy market is expected to witness significant growth in the coming years, driven by the increasing demand for plasma-derived products and advancements in plasma fractionation technology. However, companies operating in the market need to address the challenges related to the regulatory frameworks and the high cost of plasma-derived products to maximize their growth potential. Additionally, the COVID-19 pandemic has disrupted the global supply chain of plasma-derived products, which may impact the market growth in the short term. Nonetheless, the long-term growth prospects for the plasma-derived therapy market remain positive.

Plasma Derived Therapy Market Growth

The global plasma-derived therapy market is expected to continue growing at a significant rate in the coming years. The market growth is driven by several factors, including:

Increasing prevalence of chronic diseases: Chronic diseases such as immunodeficiency disorders, bleeding disorders, and neurological disorders are increasing globally, driving the demand for plasma-derived products.
Growing aging population: The aging population is increasing worldwide, and older individuals are more likely to suffer from chronic diseases that require treatment with plasma-derived products.
Increasing demand for plasma-derived products: Plasma-derived products are used in a wide range of therapeutic applications, including hematology, immunology, critical care, pulmonology, rheumatology, and others. The increasing demand for these products is driving the growth of the market.
Advancements in plasma fractionation technology: Advancements in plasma fractionation technology have led to the development of more efficient and effective plasma-derived products, driving the growth of the market.
Increasing investment in research and development: The high investment in research and development activities by key players in the market is driving the development of new and innovative plasma-derived products, further driving the growth of the market.

Based on these factors, the plasma-derived therapy market is expected to witness significant growth in the coming years. However, companies operating in the market need to address the challenges related to the regulatory frameworks and the high cost of plasma-derived products to maximize their growth potential. Additionally, the COVID-19 pandemic has disrupted the global supply chain of plasma-derived products, which may impact the market growth in the short term. Nonetheless, the long-term growth prospects for the plasma-derived therapy market remain positive.

Plasma Derived Therapy Market Competitor Analysis

The global plasma-derived therapy market is highly competitive, with several major players dominating the industry. Some of the key players in the market include:

Grifols S.A.: Grifols is a Spanish multinational pharmaceutical and chemical company that specializes in the production of plasma-derived therapies, including immunoglobulins, albumin, and clotting factors.
CSL Limited: CSL Limited is an Australian biotech company that produces and markets a range of plasma-derived and recombinant therapies for the treatment of bleeding disorders, immune deficiencies, and other medical conditions.
Octapharma AG: Octapharma is a Swiss biopharmaceutical company that specializes in the development, production, and sale of human proteins, including clotting factors, immunoglobulins, and albumin.
Shire (Takeda Pharmaceutical Company Limited): Shire, now owned by Takeda Pharmaceutical Company Limited, is a global biopharmaceutical company that produces a range of plasma-derived therapies for the treatment of rare diseases, including immunoglobulins, clotting factors, and alpha-1 antitrypsin.
Kedrion Biopharma Inc.: Kedrion Biopharma is an Italian biopharmaceutical company that specializes in the production of plasma-derived therapies, including immunoglobulins, albumin, and clotting factors.

These companies invest heavily in research and development to develop new and innovative plasma-derived therapies to treat a wide range of diseases. They also engage in strategic collaborations, acquisitions, and partnerships to expand their market presence and product portfolios.

Other notable players in the plasma-derived therapy market include Biotest AG, LFB S.A., Bio Products Laboratory Ltd., China Biologic Products Holdings, Inc., and ADMA Biologics, Inc.

Plasma Derived Therapy Market Strengths

There are several strengths of the plasma-derived therapy market:

High demand for plasma-derived therapies: Plasma-derived therapies are used to treat a wide range of medical conditions, including bleeding disorders, immune deficiencies, and neurological diseases. As a result, there is a high demand for these therapies, which drives growth in the market.
Established market players: The plasma-derived therapy market is dominated by a few large players, such as CSL Behring, Grifols, and Octapharma. These companies have established manufacturing capabilities, distribution networks, and strong relationships with healthcare providers, which gives them a competitive advantage.
Technological advancements: Advances in plasma fractionation technology have improved the purity and safety of plasma-derived therapies, which has expanded their applications and improved patient outcomes. For example, recombinant DNA technology has enabled the production of clotting factors that are free of infectious agents and can be used to treat hemophilia.
Regulatory support: Plasma-derived therapies are regulated by the FDA and other regulatory agencies to ensure their safety and efficacy. This regulatory oversight provides assurance to patients, healthcare providers, and investors that the therapies are of high quality and meet rigorous standards.
Growing patient population: The aging population, increasing incidence of chronic diseases, and expanding access to healthcare in emerging markets are driving growth in the plasma-derived therapy market. As the global population continues to grow and age, the demand for these therapies is expected to increase.

Plasma Derived Therapy Market Opportunities

There are several opportunities in the plasma-derived therapy market:

Expansion into emerging markets: Emerging markets such as China, India, and Brazil have large populations with unmet medical needs, and increasing access to healthcare. These markets present opportunities for plasma-derived therapy companies to expand their customer base and increase revenue.
New indications for existing therapies: Plasma-derived therapies are being investigated for new indications, such as Alzheimer’s disease, multiple sclerosis, and COVID-19. If these therapies are approved, they could generate new revenue streams for plasma-derived therapy companies.
Advances in plasma fractionation technology: Advances in plasma fractionation technology are enabling the development of new plasma-derived therapies with improved safety and efficacy. For example, the use of nanofiltration and other purification techniques is improving the safety of plasma-derived therapies by removing potential contaminants.
Personalized medicine: Plasma-derived therapies are being used in personalized medicine approaches, where the therapy is tailored to the patient’s specific needs. This approach has the potential to improve patient outcomes and increase demand for plasma-derived therapies.
Partnerships and collaborations: Partnerships and collaborations between plasma-derived therapy companies and academic institutions or other industry players can lead to new innovations and product development. For example, collaborations between plasma-derived therapy companies and gene therapy companies could lead to the development of gene therapies for inherited bleeding disorders.

Plasma Derived Therapy Market Weakness

One weakness of the plasma-derived therapy market is the potential risk of contamination or transmission of infectious agents through plasma-derived products. Despite rigorous manufacturing and testing processes, there is always a risk of contamination by viruses, bacteria, prions, or other infectious agents. This risk is particularly high for plasma-derived therapies that are derived from human plasma.

Another weakness of the plasma-derived therapy market is the cost of production and distribution. The manufacturing process for plasma-derived therapies is complex and expensive, and the cost of distribution can be high due to the need for specialized storage and transport. This can limit access to plasma-derived therapies for patients in low-income countries or those without adequate insurance coverage.

In addition, the plasma-derived therapy market is subject to regulatory scrutiny and evolving standards for safety and efficacy. Changes in regulatory requirements or unexpected adverse events could lead to delays in product development or even withdrawal of products from the market, which could have a significant impact on the revenue and profitability of plasma-derived therapy companies.

Plasma Derived Therapy Market Threats

There are several threats facing the plasma-derived therapy market:

Competition from alternative therapies: Plasma-derived therapies face competition from alternative therapies, such as recombinant proteins, monoclonal antibodies, and small molecule drugs. These therapies may offer advantages such as greater specificity and lower risk of contamination, which could reduce demand for plasma-derived therapies.
Regulatory challenges: The plasma-derived therapy market is subject to strict regulatory requirements for safety and efficacy. Changes in regulatory requirements or unexpected adverse events could lead to delays in product development or even withdrawal of products from the market, which could have a significant impact on the revenue and profitability of plasma-derived therapy companies.
Intellectual property challenges: The plasma-derived therapy market is highly competitive, and companies may face challenges in protecting their intellectual property rights. Patent infringement lawsuits and challenges to patent validity could limit the ability of plasma-derived therapy companies to protect their products and technologies.
Supply chain disruptions: The plasma-derived therapy market relies on a complex global supply chain for the collection, processing, and distribution of plasma. Disruptions to this supply chain, such as natural disasters, pandemics, or political instability, could lead to shortages of plasma-derived products and limit the ability of companies to meet patient demand.
Ethical concerns: The collection of plasma from paid donors has raised ethical concerns in some countries, and some patients may refuse to use plasma-derived therapies on ethical grounds. This could limit demand for plasma-derived therapies and impact the revenue and profitability of plasma-derived therapy companies.

Post Disclaimer

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Market Insight Lab journalist was involved in the writing and production of this article.